Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter].
作者信息
da Silva Vinicius Trindade Gomes, Gebrin Thiago, Paiva Wellingson Silva
机构信息
LIM 62, University of Sao Paulo Medical School, Sao Paulo, Brazil.
AC Camargo Cancer Center, Sao Paulo, Brazil.
出版信息
Neuropsychiatr Dis Treat. 2022 Oct 27;18:2453-2454. doi: 10.2147/NDT.S392309. eCollection 2022.
Abstract
摘要
相似文献
1
Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter].
Neuropsychiatr Dis Treat. 2022 Oct 27;18:2453-2454. doi: 10.2147/NDT.S392309. eCollection 2022.
2
Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas.
Radiat Oncol. 2015 Jul 30;10:156. doi: 10.1186/s13014-015-0446-0.
3
Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort.
J Neurooncol. 2021 May;153(1):55-64. doi: 10.1007/s11060-021-03741-7. Epub 2021 Mar 28.
4
Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
PLoS One. 2013;8(3):e59941. doi: 10.1371/journal.pone.0059941. Epub 2013 Mar 21.
5
Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
Int J Neurosci. 2016 Nov;126(11):1002-6. doi: 10.3109/00207454.2015.1092443. Epub 2015 Oct 6.
6
Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs.
Expert Opin Biol Ther. 2019 Feb;19(2):99-104. doi: 10.1080/14712598.2019.1559292. Epub 2018 Dec 17.
7
The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review.
Expert Rev Anticancer Ther. 2020 Mar;20(3):197-203. doi: 10.1080/14737140.2020.1736567. Epub 2020 Mar 6.
8
Atypical and anaplastic meningiomas treated with bevacizumab.
J Neurooncol. 2012 Aug;109(1):187-93. doi: 10.1007/s11060-012-0886-4. Epub 2012 Apr 29.
9
Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab.
J Neuroophthalmol. 2015 Dec;35(4):382-6. doi: 10.1097/WNO.0000000000000253.
10
Everolimus and Bevacizumab in the Management of Recurrent, Progressive Intracranial NF2 Mutated Meningioma.
Case Rep Oncol. 2019 Jan 30;12(1):126-130. doi: 10.1159/000496984. eCollection 2019 Jan-Apr.
本文引用的文献
1
Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study.
Neuropsychiatr Dis Treat. 2022 Aug 6;18:1619-1627. doi: 10.2147/NDT.S368740. eCollection 2022.
2
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Cancer Treat Rev. 2020 Jun;86:102017. doi: 10.1016/j.ctrv.2020.102017. Epub 2020 Mar 26.
3
Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review.
Surg Neurol Int. 2018 Jul 13;9:133. doi: 10.4103/sni.sni_264_17. eCollection 2018.
4
EANO guidelines for the diagnosis and treatment of meningiomas.
Lancet Oncol. 2016 Sep;17(9):e383-91. doi: 10.1016/S1470-2045(16)30321-7. Epub 2016 Aug 30.
5
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
J Neurooncol. 2016 Sep;129(2):281-8. doi: 10.1007/s11060-016-2172-3. Epub 2016 Jun 16.
Zotero 插件